171 results on '"Muller, Ilaria"'
Search Results
2. SARS-COV-2 specific t-cells in patients with thyroid disorders related to COVID-19 are enriched in the thyroid and acquire a tissue-resident memory phenotype
3. Thyroid findings in pediatric and adult patients with PTEN hamartoma tumor syndrome: A retrospective analysis, and literature review
4. Subacute thyroiditis in the SARS-CoV-2 era: a multicentre prospective study
5. Subacute thyroiditis in the SARS-Cov-2 era: a multicenter prospective study
6. Alemtuzumab-induced thyroid eye disease successfully treated with a single low-dose of rituximab
7. Autoimmune responses to thyroid/breast shared antigens to develop novel and specific therapies and diagnostics
8. Indications for treatment of subclinical hypothyroidism and isolated hypothyroxinaemia in pregnancy
9. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy
10. Response to Letter to the Editor from Lui et al: ‘Increased risk of Thyroid Eye Disease following Covid-19 Vaccination’
11. Increased Risk of Thyroid Eye Disease Following Covid-19 Vaccination
12. Increased Risk of Thyroid Eye Disease Following Covid-19 Vaccination.
13. CLINICAL AND VISUAL OUTCOMES OF DYSTHYROID OPTIC NEUROPATHY AFTER SURGICAL ORBITAL DECOMPRESSION
14. Patients with Covid-19 induced atypical thyroiditis have thyroid-resident memory T-cells specific for SARS-CoV-2
15. Increased risk of Graves' orbitopathy following Covid-19 vaccination
16. Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study
17. Long-term outcome of thyroid abnormalities in patients with severe Covid-19
18. Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies
19. sj-docx-1-mso-10.1177_20552173221142741 - Supplemental material for Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies
20. Microbiota Alterations in Patients with Autoimmune Thyroid Diseases: A Systematic Review
21. Graves' orbitopathy and subacute thyroiditis related to SARS-CoV-2 infection or vaccination: the experience of a single centre in milan, italy
22. Study of target tissue-resident immune cells in graves' disease and orbitopathy (star-GO): preliminary findings with a novel extensive immunophenotyping panel
23. Alemtuzumab-induced graves' orbitopathy successfully treated with a single dose of rituximab
24. Combining micro-RNA and protein sequencing to detect robust biomarkers for Graves’ disease and orbitopathy
25. Thyroid dysfunction related to SARS-CoV-2 vaccination: the experience of a single center in Milan
26. Impact of Covid-19 disease on thyroid function: longitudinal study
27. Subacute thyroiditis (SAT) during the COVID-19 pandemic: preliminary data from the [ldquo]ESE Covid Grant 2021[rdquo] project
28. Editorial: Mechanisms and Novel Therapies in Graves’ Orbitopathy: Current Update
29. Case Report: A Novel ARMC5 Germline Mutation in a Patient with Primary Bilateral Macronodular Adrenal Hyperplasia and Hypogammaglobulinemia
30. Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves’ Orbitopathy
31. Expression of Endogenous Putative TSH Binding Protein in Orbit
32. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy
33. SARS-CoV-2-related atypical thyroiditis
34. Efficacy of the Anti-BAFF monoclonal antibody belimumab vs methylprednisolone in active moderate-severe graves orbitopathy: Preliminary analysis of a randomized controlled trial
35. Evolution of SARS-CoV-2 related atypical thyroiditis
36. Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' Orbitopathy
37. Early Follow-up of Atypical Thyroiditis Induced by SARS-CoV-2
38. Outcomes in Alemtuzumab-Treated Patients With Thyroid Adverse Events: 6-Year Pooled CARE-MS Data (1509)
39. Asymmetry indicates more severe and active disease in Graves' orbitopathy: results from a prospective cross-sectional multicentre study.
40. Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' Orbitopathy.
41. Comparison between the efficacy of the Anti-BAFF monoclonal antibody belimumab vs methylprednisolone in active moderate-severe graves’ orbitopathy: an interim analysis
42. The antigenic link between thyroid autoimmunity and breast cancer
43. CATS II Long-term Anthropometric and Metabolic Effects of Maternal Sub-optimal Thyroid Function in Offspring and Mothers
44. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy
45. IGF-II mRNA expression in breast cancer: predictive value and relationship to other prognostic factors
46. Response to Letter to the Editor From Lui et al: “Increased Risk of Thyroid Eye Disease Following COVID-19 Vaccination”.
47. Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features
48. Controlled Antenatal Thyroid Screening II: Effect of Treating Maternal Suboptimal Thyroid Function on Child Behavior
49. Combination Thyroid Hormone Replacement; Knowns and Unknowns
50. Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.